Cite
HARVARD Citation
Campbell, C. et al. (n.d.). P.063 SUNFISH Part 1 results and Part 2 trial design in patients with type 2/3 spinal muscular atrophy (SMA) receiving risdiplam (RG7916). Canadian journal of neurological sciences. p. S31. [Online].